Validate predictive biomarkers in ovarian cancer

1. Gene symbol

 

2. Response

Relapse-free survival at 6 months (n=1347)

Relapse-free survival at 12 months (n=1282)

Pathological response (n=1022)

3. Treatment

Chemotherapy

Any

Platin

Taxane

Platin & Taxane

Docetaxel

Paclitaxel

Gemcitabine

Topotecan

Targeted Therapy

Avastin

Total: 0

Non-responders: 0

Responders: 0

4. Filters (optional)

Histology All serosus (n = 2898) endometrioid (n = 118) clear (n = 57)

Grade All 1 (n = 101) 2 (n = 738) 3 (n = 2169) 4 (n = 40)

Stage All 1 (n = 205) 2 (n = 167) 3 (n = 2455) 4 (n = 406)

Debulk All Suboptimal (n = 1124) Optimal (n = 1808)

5. Settings

JetSet only

No outliers

Show quartiles

Multi-gene analysis

Color: non-responder

Color: responder

ROC curve color

Calculate

By using the services, you agree to be bound by the Terms of Use.

Please kindly cite our paper to support further development: Fekete J & Gyorffy B: ROCplot.org: Validating predictive biomarkers of chemotherapy/hormonal therapy/anti-HER2 therapy using transcriptomic data of 3,104 breast cancer patients, Int J Cancer, 2019 Dec 1;145(11):3140-3151.,doi: 10.1002/ijc.32369.